10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
10x Genomics, Inc. filed a Current Report on Form 8-K dated March 26, 2020. The filing reports corporate governance and bylaws matters; it does not contain quarterly or annual operating results.
- Class A common stock trades on Nasdaq under the symbol TXG.
- The company identified itself as an emerging growth company.
Key Financial and Corporate Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material Changes
- The board appointed Kimberly J. Popovits as a Class II director, effective immediately.
- The board increased in size from seven to eight members.
- Ms. Popovits will receive compensation under the company’s non-employee director compensation policy, including a $40,000 annual cash retainer, a one-time option grant with a $400,000 grant-date fair market value, annual options with a $200,000 grant-date fair market value, and eligible committee retainers.
- The company entered into its standard form of indemnification agreement with Ms. Popovits.
- The board amended and restated the bylaws to provide that, unless the company consents otherwise in writing, U.S. federal district courts are the exclusive forum for claims under the Securities Act of 1933.
Outlook, Risks, Contingencies, and Unusual Items
The filing provides no financial guidance or operating outlook. The revised federal forum-selection provision may affect the venue for future Securities Act claims. The filing does not identify any specific litigation, contingency, or unusual financial item.
Investor Verification Items
- Review Exhibit 3.1 for the complete amended and restated bylaws and the precise scope of the forum-selection provision.
- Verify the terms, fair value, vesting schedule, and accounting treatment of the director option grants when disclosed in subsequent filings.
- Assess the board’s expanded composition and Ms. Popovits’s relevant healthcare and genomics industry experience.
- Consult the company’s subsequent periodic filings for any financial effects or additional disclosures arising from the appointment or compensation arrangements.